Accessibility Menu
Aspira Women's Health logo

Aspira Women's Health(OTC) AWH

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-100%
5 Year-100%
1 Year-33%
1 Month-21%
N/A
Aspira Women's Health last closing stock price
MetricPriceDate
Last closeUSD 0.282026-08-31
Aspira Women's Health stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.75%USD 0.272026-08-24
1 month-21.48%USD 0.352026-07-31
3 month-48.39%USD 0.542026-06-02
Year to date-55.76%USD 0.632025-12-31
1 year-32.7%USD 0.412025-08-29
3 year-92.24%USD 3.592023-05-12
5 year-99.5%USD 55.352021-09-01
Since inception-99.99%USD 4,800.002000-09-29

Aspira Women's Health Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$8.55M

Net Income (TTM)

-$10.01M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 13, 2025

AWH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aspira Women's Health

Aspira helps doctors find cancer risk in women with ovarian masses. Its tests use blood samples and genetic data to guide treatment decisions. These tools aim to make early detection easier for women and their healthcare providers.

Lab Coats and Algorithms: What Aspira Sells

  • OvaSuite Tests: Blood-based tests (Ova1, Overa, Ova1Plus, and OvaWatch) for assessing ovarian cancer risk in women with pelvic masses. Represents 100% of product revenue.
  • OvaWatch: Monitors risk of ovarian cancer over time in women with unclear or benign pelvic masses. Included in OvaSuite revenue.
  • Aspira GenetiX: Genetic test for inherited risk of gynecologic cancers. Revenue not separately disclosed.
  • Aspira Synergy: Cloud-based platform for decentralized access to protein and genetic testing. Revenue not separately disclosed.
  • Aspira Labs: In-house laboratory for processing all diagnostic tests. Supports all product lines.

Growth Spurts and Strategic Moves

  • Expanded OvaWatch for ongoing monitoring in Q2 2024, increasing potential test volume.
  • Signed research collaborations with Harvard Dana-Farber Cancer Institute and Brigham and Women's Hospital in 2022 and 2023.
  • Extended distribution with BioReference Health to include OvaWatch in New York in November 2024.
  • Entered international licensing with Hi-Precision Laboratories (Philippines) in 2024.
  • Received and later lost $3.5 million ARPA-H government funding for endometriosis test development in 2025.

Why Aspira Catches the Eye

Aspira uses proprietary algorithms and multi-marker tests to offer noninvasive cancer risk assessments. Its decentralized platform and direct sales model broaden access to its diagnostics. Strategic research partnerships support ongoing product development and validation.

Five Things You Need to Know

  • Revenue was $2.4 million in Q2 2025, down 0.8% from Q2 2024.
  • Gross profit margin reached 63.8% in Q2 2025, up from 58.6% in Q2 2024.
  • Net loss was $(2.7) million in Q2 2025, improving from $(3.5) million in Q2 2024.
  • OvaSuite test volume fell 11% year-over-year in Q2 2025.

Bottom Line

Aspira has focused on noninvasive diagnostics for women’s health, expanding its test portfolio and partnerships. Ongoing financial challenges and market shifts shape its current position.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

38

CEO

John Dee Fraser, MBA

Website

www.aspirawh.com

Headquarters

Austin, TX 78738, US

AWH Financials

Key Financial Metrics (TTM)

Gross Margin

58.78%

Operating Margin

-80.75%

Net Income Margin

-117.07%

Return on Equity

161.77%

Return on Capital

N/A

Return on Assets

-225.59%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$5.02M

Operating Income

-$6.90M

EBITDA

$2.79M

Operating Cash Flow

-$4.56M

Capital Expenditure

-$166.00K

Free Cash Flow

-$4.73M

Cash & ST Invst.

$477.00K

Total Debt

$2.56M

Aspira Women's Health Performance Analysis

Aspira Women's Health annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 8,184,00020.1%
20232023-12-31USD 9,154,00011.9%
20242024-12-31USD 9,182,0000.3%
20252025-12-31USD 9,216,0000.4%
Aspira Women's Health sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-4.1%
Q42025-12-31-3.3%
Q12026-03-31-11.7%
Q22026-06-304.0%
Aspira Women's Health annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -57.701251.1%
20232023-12-31USD -1.81-96.9%
20242024-12-31USD -0.93-48.7%
20252025-12-31USD -0.37-59.5%
Aspira Women's Health sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-85.7%
Q42025-12-3138.5%
Q12026-03-31112.5%
Q22026-06-30-600.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$2.05M

-14.9%

Gross Profit

$1.13M

-26.3%

Gross Margin

55.28%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

66

N/A

Net Income

-$2.42M

+9.2%

EBITDA

-$1.84M

+30.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$477.00K

-69.1%

Total Debt

$2.56M

-3.5%

Accounts Receivable

$1.49M

+16.2%

Inventory

$231.00K

-15.4%

Long Term Debt

$2.10M

-7.8%

Short Term Debt

$456.00K

+22.6%

Return on Assets

-2.26%

N/A

Return on Invested Capital

7.64%

N/A

Free Cash Flow

-$2.16M

-24.6%

Operating Cash Flow

-$2.01M

-15.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
APDNApplied DNA Sciences, Inc.
$5.62+31.62%
ARAVAravive, Inc.
$0.04-13.39%
QTTBQ32 Bio Inc.
$14.29-3.90%
NOVNNovan, Inc.
$0.09-24.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.29-0.07%
NVDANvidia
$217.44-0.02%
INTCIntel
$88.48-0.01%
NUNu Holdings
$14.48-0.01%

Questions About AWH

What is the current price of Aspira Women's Health?

Aspira Women's Health is trading at N/A per share.

What is the 52-week range for Aspira Women's Health?

Over the past 52 weeks, Aspira Women's Health has traded between N/A and N/A.

How much debt does Aspira Women's Health have?

As of the most recent reporting period, Aspira Women's Health reported total debt of $3.11M.

How much cash does Aspira Women's Health have on hand?

Aspira Women's Health reported $477.00K in cash and cash equivalents in its most recent financial results.

What is Aspira Women's Health’s dividend yield?

Aspira Women's Health does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services